Filing Flows › Comparisons › IBIO vs DWTX
iBio vs Dogwood Therapeutics: IBIO and DWTX compared
iBio is the larger company: $100K of revenue in its latest quarter (Q1 FY26) against $100K for Dogwood Therapeutics (Q3 2026).
Where the money goes: IBIO and DWTX
iBio (IBIO) · Q1 FY26
iBio, Q1 FY26: revenue $100K, net loss $5.7M, operating cash flow −$5.7M. The chart follows the revenue to costs, profit and cash.
Dogwood Therapeutics (DWTX) · Q3 2026
Dogwood Therapeutics, Q3 2026: revenue $100K, net loss $4.9M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
| iBio (IBIO) | Dogwood Therapeutics (DWTX) | |
|---|---|---|
| Latest quarter | Q1 FY26 | Q3 2026 |
| Revenue | $100K | $100K |
| Operating margin | n/m | n/m |
| Net earnings | −$5.7M | −$4.9M |
| Operating cash flow | −$5.7M | −$4.6M |
Questions
Which is bigger, iBio or Dogwood Therapeutics?
iBio is the larger company: $100K of revenue in its latest quarter (Q1 FY26) against $100K for Dogwood Therapeutics (Q3 2026).
More: iBio earnings · how iBio makes money · Dogwood Therapeutics earnings · how Dogwood Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 12, 2025; 10-Q filed Nov 6, 2026). Fiscal quarters can end on different dates. Not investment advice.